Podcasts about new drugs

Tara unpacks an intense mix of political, economic, and public safety crises in this episode. She exposes alleged surveillance of the entire Republican ecosystem, explores Trump's global strategy to counter China's control over rare earth minerals, and breaks down the rising threat of synthetic opioids like xylazine and nidazines. Tara also examines financial markets, the U.S. economic landscape under tariffs, and controversial funding from organizations like the Gates Foundation tied to China's military. From domestic political battles to international negotiations, this episode covers the high-stakes conflicts shaping America today. Politics, power, and peril—what they're not telling you. Tara provides an exhaustive look at recent political and global developments, beginning with alleged massive surveillance targeting the Republican Party and its affiliates. She examines Trump's ongoing efforts to counter China's economic leverage on rare earth minerals and the deadly new synthetic opioids infiltrating the U.S. She also delves into financial news, including tariffs, inflation, and stock market trends, highlighting how economic manipulations affect everyday Americans. Tara further reveals connections between U.S. funding, the Gates Foundation, and China's military, emphasizing the critical stakes of global trade, public health, and political accountability. This episode blends investigative reporting with analysis of national security, public safety, and political strategy.

The new Frankenstein movie hits theaters, a deep-dive into the pornography-obsessed subculture known as "gooning," and why high-potency marijuana use is landing some users in the ER. Song of the Week - "The Fate of Ophelia" - Taylor Swift Click here for the lyrics. Elsewhere in Culture: For the first time since 1990, there are no rap songs on the Billboard Top 40—marking the end of a 35-year streak. K-pop sensation BTS will end their three-year hiatus next year, embarking on a tour and releasing new music. A high school teacher went viral with a post on TikTok that showed the extreme way students reacted to his instruction to write a five-sentence paragraph.The as-yet-unidentified jewelry robbers who pulled off a heist at the Louvre were the topic of this week's social media fascination. YouTube is adding more content restrictions to better protect minors from encountering two types of content: online gambling and video games that depict graphic violence. Check out our Ask Axis episode "How do I talk to my adult son about porn and screen addiction?" Check out Fight the New Drug for teens. Check out Pure Desire for adults. Become a monthly donor today, join the Table. For more Axis resources, go to axis.org.

America's hospitals will soon face an unprecedented rebate-based prescription drug model, come Jan. 1 – that's when there will be as many as 10 major drugs subject to Medicare price caps. This development is expected to create administrative and financial challenges for hospitals, which will have to pay the commercial price for such drugs while waiting for the rebates.For analysis and context, Maureen Testoni, president and CEO for 340B, will be the special guest during the next live edition of Monitor Monday. She will also review a recent Congressional Budget Office (CBO) report, featured in a recent Senate committee hearing, that includes some misrepresentations about why the 340B program has grown in recent years.As a special bonus, the longtime Internet broadcast produced by RACmonitor, will feature senior healthcare consultant Drew Updike, MD, who will recognize the tireless work being performed by the employees of the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) who continue to work despite the federal shutdown, now in its fifth week.The weekly broadcast will also include these instantly recognizable features:Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.Legislative Update: Adam Brenman, senior legislative affairs analyst for Zelis, will report on the news happening at the intersection of healthcare and congressional action.

“Europe is missing too many innovations.”I had the pleasure of welcoming Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio — an innovative company that accelerates biopharma market entry across Europe.By combining capital, deep expertise, and industry knowledge, Xcube.Bio helps mitigate risks and launch transformative solutions.Pierre-Henri is a leading voice in pharmaceutical innovation and healthcare transformation. In this episode, he shares a bold vision to bridge one of Europe's most urgent healthcare gaps: the slow access to new drugs for European patients.In this conversation, we discuss:◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.◾️ The consequences for patients, innovation, and the competitiveness of Europe's healthcare ecosystem.◾️ Pierre-Henri's proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.Many thanks to Xcube.Bio for supporting this episode. Their partnership allows us to push our explorations further — but the spirit of Pharma Minds remains unchanged: full editorial independence and complete freedom in choosing our guests.—Find Pierre-Henri Belin:LinkedIn: https://www.linkedin.com/in/phbelin/?originalSubdomain=chXcube.Bio: https://xcube.bio/Resources mentioned in the episode:

Hundreds of breakthrough treatments are transforming patients' lives in the US — but still aren't available in Europe.In this short extract, Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio, reveals the shocking scale of this innovation gap… and why it's growing.The full episode drops tomorrow on Pharma minds — don't miss it!What you will learn in the full episode of tomorrow :◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.◾️ The consequences for patients, innovation, and the competitiveness of Europe's healthcare ecosystem.◾️ Pierre-Henri's proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.See you tomorrow!---

AI is everywhere these days, and though there's debate about how useful it is, one area where experts think it could be game-changing is scientific research. It promised to be particularly useful for speeding up drug discovery, an expensive and time-consuming process that can take decades. But so far, it hasn't panned out.The few AI-designed drugs that have made it to clinical trials haven't been approved, venture capital investment in these efforts has cratered in the last few years, and many startups have shut their doors. So why has it been so hard to make AI-designed drugs? What are the fundamental issues, and what does the future of this research look like?Joining Host Ira Flatow with some answers is Peter Coveney, who studies how chemistry discoveries can be sped up with algorithms and computers.Guest: Dr. Peter Coveney is a professor and director of the Centre for Computational Science at University College London.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

One of the things I'm seeing with the rise of GLP-1 weight loss drugs is other companies trying to use these drugs as a profit center. Today we'll look at a drug that is seeking approval to help those who take GLP-1s avoid some of the adverse events. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Stocks dropping across the board, as President Trump threatens a tariff increase on China. The sectors getting hit the hardest, and where government layoffs are beginning as the shutdown continues. Plus Another drug pricing deal in the pharma space. The company striking a deal with the President, and the reaction from the health care sector.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Endometriosis is estimated to affect one in ten Kiwi women, it can cause debilitating pain and really affect women's ability to live life to the fullest. But today we saw an exciting headline - the first treatment for endometriosis in nine years is now registered in New Zealand. It's called Ryeqo. Professor Neil Johnson, a gynaecologist from the Auckland Gynaecology Group, former president of the World Endometriosis Society, and an investigator for the international trials of Ryeqo chats to Jesse.

The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But it was business as usual at the CDC, which adopted the recent recommendations of its newly revamped advisory committee on chickenpox and COVID-19 vaccines. And another senior leader, National Institute of Allergy and Infectious Diseases Director Jeanne Marrazzo, was fired last week, after filing a whistleblower report.  Across the country, cell and gene therapy leaders arrived in Phoenix for the annual Meeting on the Mesa, as the space remains in a state of flux—with regulatory and M&A momentum being stalled by commercial and market challenges. Takeda, for one, is looking to offload its cell therapy platform after years of hefty investment.  President Donald Trump's long-awaited tariffs did not hit on Oct. 1 as promised. But in the face of the looming levies, Pfizer signed a drug pricing deal with the White House that provides a three-year exemption. Amgen appears to be climbing onboard as well, announcing that its lipid-lowering drug Repatha will be available at a steep discount. These moves are all well and good for Big Pharma players, but a recent report from CRB reveals most smaller biopharma companies are not planning any investments to offset tariffs.  In our weekly weight loss segment, Skye Bioscience's cannabinoid receptor 1-targeting candidate nimacimab failed to outpace placebo in reducing body weight but elicited “intriguing synergy” in combination with Novo Nordisk's Wegovy, according to William Blair analysts. And regulatory documents shed further light on Pfizer's $4.9 billion takeover of Metsera, in which the New York pharma beat out two higher bidders for the promising obesity startup.  Finally, make sure to check out The 5 Most Powerful Women in Biopharma and BioSpace's inaugural 40 Under 40, highlighting 40 young leaders who have made an impact on the biopharma industry.  

A leading oncologist has warned that public patients are being denied ­powerful new cancer drugs which could keep them alive for longer or in some cases, cure them, while these same drugs are available to people who have health insurance. The oncologist in question, Dr. Michael McCarthy, a cancer specialist in Galway University Hospital, who has long campaigned to end the inequity, is now among a number of senior specialists who are supporting a letter to Health Minister Jennifer Carroll MacNeill proposing a co-funded early-access programme. Dr. Michael McCarthy, Consultant Oncologist at Galway University Hospital, joined Pat Kenny on the show.

AI science advances are FINALLY happening while OpenAI's Sam Altman & NVIDIA's Jensen Huang send billions back and forth. If $100 billion is a drop in the well, how much do they need? Plus, ChatGPT is causing divorces, new AI video models Kling 2.5 Turbo & Wan 2.5, Suno drops v5 & Gavin drops the fact that he's not *loving* Kevin's mustache. Oh & we're getting ready for the launch of AndThen, our new start up! Sign up now in the link below.   Get notified when AndThen launches: https://andthen.chat/ Come to our Discord to try our Secret Project: https://discord.gg/muD2TYgC8f Join our Patreon: https://www.patreon.com/AIForHumansShow AI For Humans Newsletter: https://aiforhumans.beehiiv.com/ Follow us for more on X @AIForHumansShow Join our TikTok @aiforhumansshow To book us for speaking, please visit our website: https://www.aiforhumans.show/   // Show Links // AI Psychedelics Are Here https://www.wired.com/story/a-startup-used-ai-to-make-a-psychedelic-without-the-trip/ Nvidia to Invest 100b In OpenAI (a lot of which will be spent on Nvidia chips) https://www.cnbc.com/2025/09/22/nvidia-openai-data-center.html “A Hundred Billion Is A Small Dent In It” Sam on CNBC https://x.com/sundeep/status/1970311723262656638 Sam Altman on “Abundant Intelligence” https://blog.samaltman.com/abundant-intelligence How will OpenAI pay for all this? Advertising. https://x.com/alexeheath/status/1970998934278676710 New models incoming that will be more that GPT-5 Pro  https://x.com/sama/status/19698 35407421374910 Meanwhile… ChatGPT is Causing Divorces https://futurism.com/chatgpt-marriages-divorces Suno v5 https://x.com/SunoMusic/status/1970583230807167300 Kevin's Terrible Mustache Https: //suno.com/s/j0b9Ukgd2CbtHVbu Kling 2.5 Is Pretty Good https://x.com/Kling_ai/status/1970439808901362155 Wan 2.5 With Audio https://blog.fal.ai/wan-2-5-preview-is-now-available-on-fal/ Wan Darth Vader https://x.com/fofrAI/status/1970877788384337977 Skild AI Robot Gets Legs Sawed Off & Learns To Walk Again https://x.com/SkildAI/status/1970940614234771579 Unitree's Anti-Gravity Mode https://x.com/UnitreeRobotics/status/1970039940022239491 If Stalin's Life Was A Video Game https://www.reddit.com/r/ChatGPT/comments/1npbwdr/if_they_made_a_video_game_about_the_life_of_stalin/ Carboarding: The Movie https://www.reddit.com/ r/ChatGPT/comments/1nmdipq/carboarding_the_movie/  

Date: Sept 16, 2025 Reference: Prada et al. Evaluation of the evidence on acetaminophen use and neurodevelopmental disorders using the Navigation Guide methodology. Environ Health. August 2025 Guest Skeptic: Dr. Andrew Martin is an emergency physician practicing in Jacksonville, Florida.  Case: A 27-year-old at 24 weeks' gestation presents to the emergency department (ED) with fever (38.6 °C), myalgias, and […] The post SGEM#485: I Want a New Drug – One Not Associated with Neurodevelopmental Disorders first appeared on The Skeptics Guide to Emergency Medicine.

Move over Sinaloa Cartel, there's a new kingpin in town

Is pornography hijacking your child's brain? In this essential episode of Parenting Great Kids with Dr. Meg Meeker, Dr. Meg sits down with Parker Hymas, Director of Public Outreach at Fight The New Drug, to expose the growing threat pornography poses to kids and teens in today's digital-first world.

In this weeks Fear Of Missing Out report we cover what the Trump administration is doing to address threats to people of faith. Many are worried about a drug that can be bought at your local gas station as the 4th opioid wave. Alligator Alcatraz is open again and should there be a ban on gun ownership by Trans identifying individuals. There was a significant death this week in the world of fashion and we end with a funny comparison of speech of a politician.

Born with NF1-PN, a rare genetic disorder, Austin Fields spent his childhood learning how to live in a body riddled with benign tumors. Though removal surgery is the main treatment for this painful condition, a new medication has recently been approved for adults with NF1-PN. Our experts explain what it's like to live with this condition and how this novel drug is enhancing patients' quality of life. Learn More: https://radiohealthjournal.org/the-new-drug-that-shrinks-tumors-for-patients-with-nf1-pn Learn more about your ad choices. Visit megaphone.fm/adchoices

Carfentanil is making it's way through the Valley. We talked to the SAC of the DEA this hour about it and how to protect your kids. 

The pharmaceutical industry is pursuing what some consider to be the holy grail: developing and licensing the first drug that slows the body's natural aging process.Writer: Jon Ungoed-ThomasProducer: Casey Magloire Host: Tomini Babs Executive Producer: Rebecca Moore Hosted on Acast. See acast.com/privacy for more information.

Some drugs used to treat breast cancer might also be used to prevent it, but the hot flashes and other troublesome side effects make that an unlikely choice for many women. Johns Hopkins Kimmel Cancer Center director William Nelson says … Can a new drug that helps hot flashes herald a way to prevent many breast cancers? Elizabeth Tracey reports Read More »

Miguel Salguero-Olivares is waiting for trial in the Durham County Detention Center. On Tuesday, a court hearing focused on charges that he had meth inside the jail. It comes as his defense team continues to build its case for his trial for the murder of Faith Hedgepeth. WRAL's Monica Casey breaks down these new developments.

On this week's Headlines edition of the podcast, we start by summing up the most relevant details from the massive budget bill recently passed by Congress and signed by President Trump. We also discuss The Imprint's recent reporting on youth who enter foster care due to their behavioral health needs, and not because of abuse or neglect, and describe the new policies in New Mexico around removal of newborns who test positive for certain drugs. Reading RoomWhite House Watchhttps://imprintnews.org/special-series/white-house-watchThe Trump Admin is Withholding over $6 Billion in Education Grants for Schoolshttps://www.npr.org/2025/07/01/nx-s1-5453457/trump-school-funding-grants Trump Freezes Grant Funding, Upending School Budgetshttps://edsource.org/2025/california-education-federal-funding-cuts-teachers-english-learners/735665When Minnesota ParentsGive Up Their Kids to Foster Care: An Imprint Look at a Nationwide Predicamenthttps://imprintnews.org/child-welfare-2/when-minnesota-parents-give-up-their-kids-to-foster-care-an-imprint-look-at-a-nationwide-predicament/261820Michigan Justice Seeks ‘No-fault' Pathway to State Aid for Parents Who Can't Manage Kids' Mental Health Needshttps://imprintnews.org/top-stories/michigan-justice-seeks-no-fault-pathway-to-state-aid-for-parents-who-cant-manage-kids-mental-health-needs/262500Texas Lawmakers Take On Little-Known Pathway Into Foster Care: Parents Seeking Mental Health Treatment for Their Childrenhttps://imprintnews.org/top-stories/texas-lawmakers-take-on-little-known-pathway-into-foster-care-parents-seeking-mental-health-treatment-for-their-children/259701New Mexico Governor Plans to Crack Down on Families with Babies Born Addictedhttps://www.santafenewmexican.com/news/legislature/governor-plans-to-crack-down-on-families-with-babies-born-addicted/article_755e8552-554c-49ed-864f-df14dd1abaf4.html

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentExciting news in the world of oncology as a new breakthrough in cancer treatment has been announced. Researchers have discovered a novel therapy that targets specific mutations in cancer cells, leading to significantly improved outcomes for patients. This groundbreaking treatment is set to revolutionize the way we approach cancer care and could potentially save countless lives in the future.## FDA Approval for New DrugIn other news, the FDA has granted approval for a new drug that shows promising results in the treatment of a rare genetic disorder. This drug has undergone rigorous testing and has been shown to be both safe and effective in clinical trials. The approval of this medication represents a major milestone in the field of rare disease treatment and offers hope to patients who previously had limited options for managing their condition.## Collaboration between Pharmaceutical CompaniesA collaboration between two leading pharmaceutical companies has been announced, with the goal of developing innovative therapies for a range of diseases. This partnership brings together the unique expertise and resources of both companies, potentially leading to the discovery of new treatments that could benefit patients worldwide. This collaboration highlights the importance of working together to address unmet medical needs and advance the field of medicine.## Advancements in Gene TherapyExciting advancements have been made in the field of gene therapy, with researchers reporting promising results in early clinical trials. Gene therapy has the potential to treat a wide range of genetic disorders by replacing or modifying faulty genes. These latest developments represent a significant step forward in the field of genetic medicine and offer hope to patients who previously had limited treatment options.## ConclusionIn conclusion, these recent developments in the world of Pharma and Biotech are not only groundbreaking but also offer hope for patients facing serious medical conditions. From breakthroughs in cancer treatment to advancements in gene therapy, the future of medicine is looking brighter than ever. Stay tuned for more updates on these exciting developments as we continue to follow the latest news in Pharma and Biotech.

Under a new proposal, Washington state taxpayers would foot the bill for addicts to get hard drugs. Prepare for sweeping statewide reparations. Congresswoman introduces “housing not handcuffs” bill. Teachers' union trains members on how to obstruct ICE. Elon Musk threatens to derail midterms over Big Beautiful Bill.

BUFFALO, NY – July 1, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Optimizing enfortumab vedotin plus pembrolizumab therapy.” First authors Elias Antoine Karam of the Gustave Roussy and Saint-Joseph University of Beirut and Yaghi César Céline from the Saint-Joseph University of Beirut, along with their colleagues, reviewed recent developments about treating advanced urothelial carcinoma (aUC), an aggressive form of bladder cancer. Their review highlights how combining enfortumab vedotin and pembrolizumab as a first-line treatment offers a major improvement for patients with limited options and poor prognoses. Advanced urothelial cancer has traditionally been treated with platinum-based chemotherapy, which often causes serious side effects and offers limited long-term benefit. Many patients are even ineligible for it due to underlying health conditions. The new combination presents a more effective and better-tolerated alternative, as shown in recent clinical trials reviewed by the authors. Enfortumab vedotin targets Nectin-4, a protein present in most urothelial cancer cells, delivering a cancer-killing agent directly into tumors. Pembrolizumab helps the immune system detect and destroy cancer cells. Together, they have shown strong results in extending survival with fewer serious side effects than chemotherapy. These findings led to FDA approval in 2023 for use in a broad range of patients, including those unable to tolerate traditional treatments. “In the phase II KEYNOTE-052 study, pembrolizumab demonstrated significant efficacy as initial therapy in patients with aUC who were ineligible for a cisplatin-based regimen.” The review also compares this new approach with other evolving strategies, such as therapies using nivolumab and chemotherapy combinations. Among current first-line options, enfortumab vedotin and pembrolizumab have produced the most promising outcomes. However, the best course of action following disease progression remains unclear. Other important challenges raised in the review include the high cost of the new therapies, limited patient access to them, and the absence of reliable biomarkers to predict individual response. The authors call for further studies to refine treatment strategies and explore blood-based tools that could guide therapy decisions and minimize side effects. This review offers a clear summary of how recent clinical advances are reshaping the treatment of aUC. It reflects a shift away from traditional chemotherapy toward immunotherapy and targeted, personalized treatments that aim to extend survival and improve quality of life. DOI - https://doi.org/10.18632/oncotarget.28741 Correspondence to - Elias Antoine Karam - eliaskaram18@gmail.com Video short - https://www.youtube.com/watch?v=VrTXaF2qW2k Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28741 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, advanced urothelial carcinoma (aUC), enfortumab vedotin, pembrolizumab, treatment strategies, bladder cancer To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of drugs covered by the Medicare Drug Price Negotiation Program of the Inflation Reduction Act (IRA). Now there are a total of 25 drugs that are covered by the IRA’s requirement that the Department of Health and Human Services (HHS) pays only a “fair price” for selected drugs covered by Medicare Part D. The new prices are set to take effect on January 1, 2027. What implications does this have for patients and for drug research and development? Join the discussion on the 'fair price' mandate and its impact on pharmaceutical innovation. Featuring: Lisa Ouellette, Deane F. Johnson Professor of Law at Stanford Law School Dan Troy, Managing Director at the Berkeley Research Group Brad Watts, Senior Vice President at the Global Innovation Policy Center, U.S. Chamber of Commerce [Moderator] Adam Mossoff, Professor of Law at Antonin Scalia Law School, George Mason University

Welcome to the Summer 2025 "Best of Series," where we replay our most popular episodes of the year so far. Whether you are relistening or hearing them for the first time, we pray that you are blessed, encouraged, and challenged. So sit back and enjoy; we'll see you back in August for all-new episodes. Today's episode is part of one of our Pornography Series with Ted Shimer and Hunter House.

TheECmethod.co.uk

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The biopharma industry is currently facing challenges such as tariff threats and regulatory upheaval. The market has been described as 'moribund' with the need for companies to survive in these tough times. Recent top stories include biotech's struggle with investor pullback due to new tariffs, HHS vaccine requirements sparking controversy, and layoffs in major biopharma companies. AGC Biologics will be at Bio International to showcase their global capabilities in drug production. FDA and NIH are shifting away from animal research, China remains a key source for new drugs despite tariffs, and the top highest-paid pharma CEOs are highlighted. The importance of understanding Trump's MFN executive order and the most active corporate VCs in pharma are also discussed.

Alzheimer's disease, the most common form of dementia, affects nearly 600,000 Australians. But there is renewed hope, with Australia's Therapeutic Goods Administration approving a new medication that could offer relief to those living with the condition. Researchers say the drug represents a major breakthrough in the ongoing quest for more effective treatments.

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.

Health authorities in Australia have approved a new drug that could slow the progression of Alzheimer's.

In this conversation, Parker discusses his journey with Fight the New Drug, an organization dedicated to raising awareness about the harmful effects of pornography. He shares insights on the changing public perception of pornography, the importance of education and awareness, and the societal impacts of porn consumption. The discussion also touches on the ethics of pornography, the challenges of sexting among youth, and the crucial role parents play in guiding their children through these issues. This conversation delves into the multifaceted impacts of pornography on individuals and society, emphasizing the importance of home education, mental health, and the role of live events in raising awareness. The speaker discuss the escalating nature of pornography consumption, its detrimental effects on mental health, and the significance of research in informing the public. They also highlight the need for diverse influencer engagement and faith-based approaches to effectively communicate the message. Personal stories of recovery and the importance of self-care in addressing heavy topics are also explored. Got a Question? It Could Be on the Podcast! Submit It Through This Form Find Out More About My DeepClean Recovery Program Here Get A Free Copy of The Last Relapse, A Blueprint For Recovery Watch Sathiya on Youtube For More Content Like This   Chapters: 00:00 Introduction to Fight the New Drug 03:02 Parker's Journey with Fight the New Drug 05:57 Public Perception of Pornography 09:00 Educational Approaches to Pornography Awareness 11:54 Societal Impacts of Pornography 14:56 The Ethics of Pornography 18:12 Sexting and Its Consequences 20:57 Parental Guidance on Pornography and Sexting 28:32 The Role of Home Education in Addressing Pornography 29:00 Understanding the Individual Impact of Pornography 30:18 Mental Health and Pornography Consumption 33:04 Future Strategies for Raising Awareness 36:24 The Importance of Live Events in Education 37:08 The Role of Research in Awareness 38:44 Pandemic Effects on Pornography Consumption 40:28 Influencers and Celebrity Voices on Pornography 42:41 Diverse Influencer Engagement Strategies 44:20 Faith-Based Approaches to Pornography Education 47:10 Self-Care in Heavy Conversations 51:11 Powerful Stories of Recovery and Awareness

In PBSE Episode 280, Mark & Steve address the complex challenge faced by betrayed partners—especially those healing from porn or sex addiction in their relationships—who want to guide their teenage children toward healthy sexuality. It begins by acknowledging the emotional burden and conflict many betrayed partners feel, especially when trying to teach their children something they themselves are still struggling to reclaim. Drawing from a listener's heartfelt question, the hosts emphasize that children are already receiving sexual messaging from the world around them, making it crucial that parents step up to provide a healthy, grounded counter-narrative rooted in respect, consent, and emotional connection.The article challenges the outdated concept of “the talk” by promoting a new paradigm: sexuality should be an ongoing, evolving, and age-appropriate conversation that unfolds over years, not moments. Parents are encouraged to reflect on their own stories, recognize internal shame or awkwardness, and ensure that their emotional energy during these talks doesn't unintentionally pass discomfort or judgment onto their children. The authors stress that kids are emotional sponges, and how parents talk about sex—more than just what they say—deeply influences how their children feel about their own bodies, desires, and relationships. This is why intentionality and preparation matter more than perfection.Practical tools and resources are also discussed, such as those from Fight the New Drug, Defend Young Minds, and Covenant Eyes. The article affirms that even when a co-parent is absent or unsafe to engage in these conversations, there are still ways to ensure kids have positive, trustworthy influences. By speaking truthfully, embracing healthy sexual values, and modeling openness, betrayed partners can break generational cycles of secrecy, shame, and dysfunction. Each conversation—no matter how imperfect—is a step toward a legacy of empowerment, honesty, and loving connection.For a full transcript of this podcast in article format, go to:  As a Betrayed Partner, How do I Talk to my Teenage Kids About Healthy Sexuality?Learn more about Mark and Steve's revolutionary online porn/sexual addiction recovery and betrayal trauma healing program at—daretoconnectnow.comFind out more about Steve Moore at:  Ascension CounselingLearn more about Mark Kastleman at:  Reclaim Counseling Services

Ready to transform your life after discovering his betrayal (cheating, p*rn use, etc.)? Book a 1-on-1 Support Call: click here Self-paced, online course "Betrayal Survival Guide": Click here Apply for my 3-month coaching package: Click here P*rn addiction recovery resource: Click here Click below for more resources: TikTok Instagram Join my Women's Support Group "WTF Do I Do Now?" Website **Please subscribe and rate the show so the algorithm can help more girls find this resource and know they aren't alone in their healing journey from his cheating, p*rn use, etc.!

Show Notes Episode 492: You STILL Want A New Drug Part 2 of the Crack Epidemic This week Host Dave Bledsoe thought he was done drinking but discovered his credit card company had (Foolishly) upped his credit limit. (This will not end well for either of them) On the show this week we deliver part two of the crack epidemic talking about all the lies told by white people to scare themselves about black people doing crack.  Along the way we find out that Dave is a little snitch.  Then we dive right into a totally unnecessary lesson on the historical geography of Washington DC. (Flimsiest pretext yet for a tangent.) Then we learn how the President of the United States entrapped a high school student to sell him crack. (Every word of that is true and mostly accurate.) From there we discover how Ronald Reagan (HE'S BACK!) set the stage for the mass incarceration of two generations of Black Men. (We're sure it was an accident.) Finally, we explain the most heinous lie of the whole damn lot of them, about moms, babies and medicine. Our Sponsor this week is Creative Problem Solving, fixing it by making it worse.  We open the show with Poppy Bush sharing his stash and close with Carson McKee who wonders if it will EVER be over? Show Theme: Hypnostate Prelude to Common Sense The Show on Bluesky: https://bsky.app/profile/whatthehellpodcast.bsky.social The Show on Facebook: https://www.facebook.com/whatthehellpodcast/ The Show on Youtube:  https://www.youtube.com/channel/UCjxP5ywpZ-O7qu_MFkLXQUQ The Show on Instagram: https://www.instagram.com/whatthehellwereyouthinkingpod/ Our Discord Server: https://discord.gg/kHmmrjptrq Our Website: www.whatthehellpodcast.com Patreon:  https://www.patreon.com/Whatthehellpodcast The Show Line: 347 687 9601 Closing Music: https://youtu.be/eofltXeiSVM?si=2IRyTVkIuYb2uI6m Buy Our Stuff: https://www.seltzerkings.com/shop Citations Needed: The Inside Story Of The Lafayette Park Crack Bust That George H.W. Bush Used To Sell The War On Drugs https://dcist.com/story/18/12/04/the-inside-story-of-the-lafayette-park-drug-bust-that-george-h-w-bush-used-to-sell-the-war-on-drugs/ The Disparate Treatment of Crack Cocaine and the Opioid Epidemic: Unveiling Racial Bias in Drug Policy https://www.scu.edu/government-ethics/resources/the-disparate-treatment-of-crack-cocaine-and-the-opioid-epidemic/#:~:text=Shortly%20thereafter%2C%20policymakers%20enacted%20the,impact%20on%20the%20Black%20community. Cracking Cocaine Myths https://pepperdine-graphic.com/cracking-cocaine-myths/ Demographic and socioeconomic correlates of powder cocaine and crack use among high school seniors in the United States https://pmc.ncbi.nlm.nih.gov/articles/PMC5066573/ Governmental efforts to address the epidemic https://www.britannica.com/topic/crack-epidemic#ref334577 Just Blowing Smoke? https://magazine.emory.edu/issues/2013/autumn/of-note/just-blowing-smoke/index.html Revisiting the ‘Crack Babies' Epidemic That Was Not https://www.nytimes.com/2013/05/20/booming/revisiting-the-crack-babies-epidemic-that-was-not.html Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

Show Notes Episode 491: You Want A NEW Drug? Part 1 of the Crack Epidemic This week Host Dave Bledsoe found himself unexpectedly in a serious situation when we staggered into an Irish wake and had to pretend he was cousin Eamon from Cork. (He was quickly figured out because his fake Irish accent kept sounding more Jamaican.) On the show this week we unexpectedly found ourselves tackling a topic way more serious than this dumb show should be allowed, the Crack Epidemic. Along the way we discover that Dave was a tattle tale growing up and then dive right into the backstory of crime in the 70s, 80's and 90s. (This is where everything started going wrong.) Then we learn how someone (could be kids from Barbados could be kids from Berkeley, or the CIA) learned how to make crack from stuff in your cleaning cabinet.  We take a look at the economic and social conditions that made the crack trade so popular in the inner city. (This is where shit got real) before laying out crack's real top customers.  (White people, surprise!) Then we look at the impact of crack on the communities that sold it. That is when the show became a two-parter. Our Sponsor this week is Clean Cut Baking Soda, don't step on your product dirty, use Clean Cut!  We open with Bette Midler telling kids that crack is whack and close with The Comatose Brothers seeking a second pharmaceutical opinion. Show Theme: Hypnostate Prelude to Common Sense The Show on Bluesky: https://bsky.app/profile/whatthehellpodcast.bsky.social The Show on Facebook: https://www.facebook.com/whatthehellpodcast/ The Show on Youtube:  https://www.youtube.com/channel/UCjxP5ywpZ-O7qu_MFkLXQUQ The Show on Instagram: https://www.instagram.com/whatthehellwereyouthinkingpod/ Our Discord Server: https://discord.gg/kHmmrjptrq Our Website: www.whatthehellpodcast.com Patreon:  https://www.patreon.com/Whatthehellpodcast The Show Line: 347 687 9601 Closing Music: https://youtu.be/h8aBWQATw1w?si=2J7w7W9ZlppzyEfL Buy Our Stuff: https://www.seltzerkings.com/shop Citations Needed: Crack Cocaine Fast Facts https://www.justice.gov/archive/ndic/pubs3/3978/index.htm Crack: A cheap and deadly cocaine is a fast-spreading menace https://time.com/archive/6706314/crack-a-cheap-and-deadly-cocaine-is-a-fast-spreading-menace/ The Severely-Distressed African American Family in the Crack Era: Empowerment is not Enough  https://pmc.ncbi.nlm.nih.gov/articles/PMC2565489/pdf/nihms-66258.pdf An Era of Drug Destruction: From Heroin to Crack Cocaine https://collaborativehistory.gse.upenn.edu/stories/era-drug-destruction-heroin-crack-cocaine Are the Wages of Sin $30 an Hour? Economic Aspects of Street-Level Drug Dealing https://journals.sagepub.com/doi/10.1177/0011128792038004005?icid=int.sj-full-text.similar-articles.7 Cocaine in the 1980s https://opentextbooks.clemson.edu/hlth4000holcombtugman/chapter/cocaine-in-the-1980s/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a textIn this episode of Going Under: Anesthesia Answered with Dr. Brian Schmutzler, Brian and Vahid talk about a new drug that has surfaced in the medical industry that could be a breakthrough in how doctors treat pain. Could this be a game-changer and change the way physicians administer opioids?Have a question for Dr. Brian Schmutzler? Submit them to any of the social media pages below or on his website at https://www.drbrianschmutzler.com/Facebook: https://www.facebook.com/drbrianschmutzlerInstagram: https://www.instagram.com/drbrianschmutzlerTikTok: https://www.tiktok.com/@drbrianschmutzler?lang=enProvider or Medical Student?? Subscribe to his Patreon Page to get exclusive content and access to Medical Blocks:https://www.patreon.com/user?u=89356957&utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator&utm_content=join_linkThanks to our show sponsor: Butterfly Networkhttps://store.butterflynetwork.com/us/en/?rsCode=BRIAN25Support the show

Protecting Kids from the Dangers of Pornography   In this episode, Andy discusses the protection of children from the dangers of pornography with Parker Hymas, Director of Public Outreach at Fight The New Drug. They take a hard look into the different ways children might be exposed to porn, the impacts it has on their mental health and behavior, and effective strategies for parents to have open conversations about this sensitive issue. Additionally, they discuss the impact of platforms like OnlyFans on modern society and self-exploitation.   For more from Fight The New Drug: https://fightthenewdrug.org Take control of your data with DeleteMe. Because they sponsor the podcast you can get 20% off a privacy plan from DeleteMe with promo code: DAD.  Level Up your parenting with my ebook about protecting your kids while gaming online. Connect

Some hugely profitable drugs are targeted under new price controls. Big Pharma has been spending millions to fight them tooth and nail.Order Sharyl's new bestselling book: “Follow the $cience.” Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BLACKOUT COFFEE!! Try Morning Reaper! You can get 20% off your first order- Just head to http://blackoutcoffee.com/hotseat and use code "hotseat" at checkout! Get Healthy! https://makewellness.com/273028 Join the Audio Podcast! https://podcasts.apple.com/us/podcast/the-hotseat/id1792653414 All the Links! https://linktr.ee/Toddspears1776 MERCH!!! https://www.redpillthreads.com/hotseat

Is pornography just a private matter—or is it rewiring our kids' brains, damaging relationships, and fueling exploitation? In this urgent and eye-opening episode of The 1000 Hours Outside Podcast, Ginny Yurich speaks with Parker Hymas from Fight the New Drug, a non-religious, non-legislative organization dedicated to exposing the harmful effects of porn through science, facts, and personal accounts. Together, they dive into what makes today's porn fundamentally different from past generations, how early exposure (sometimes as young as age 7) is shaping children's mental health and relational expectations, and why conversations—not just filters—are the true solution. Parker breaks down the research, offers hope for healing, and shares practical tools for parents, educators, and anyone who cares about kids. If you've been avoiding this topic, this is the episode you can't afford to miss. ** All Fight the New Drug resources are free!! Learn more about Fight the New Drug and all they have to offer here Bring Fight the New Drug to your organization by going here Parents, find special resources just for you from Fight the New Drug here Learn more about your ad choices. Visit megaphone.fm/adchoices

A new drug shows signs of delaying Alzheimer's symptoms in those who are genetically predisposed to the disease and a surprising skeleton discovery could rewrite our history of the pyramids. Plus, On This Day in History, the first cherry blossom trees are planted in Washington D.C. Anti-amyloid drug shows signs of preventing Alzheimer's dementia | ScienceDaily Researchers find a hint at how to delay Alzheimer's symptoms. Now they have to prove it | AP News Strange skeleton discovery could rewrite our history of the pyramids | BBC Science Focus Magazine Japanese cherry trees planted along the Potomac | March 27, 1912 | HISTORY Mrs. Taft and the Cherry Blossoms - White House Historical Association Sponsored by Factor -use code coolstuff50off to get 50% off your first box plus free shipping.  Contact the show - coolstuffcommute@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Friends, there is so much great information in this episode! I am thrilled to share it with you. Today I get to talk with Parker Hymas of Fight the New Drug. I didn't think I could be a bigger fan of this organization but after this episode, I am!! They are not fighting porn in a timid and embarrassed way. They are bold and brave in their message. But also speak with compassion and true care for anyone caught in the web of porn consumption. What they really want is to inspire change by educating people about the harm porn does. This episode is extra helpful if you have older teens or young adutls.  In this episode we talk about how porn harms everyone and no one is immune to it, that many teens and young adults turn to porn for their sex education and that no one has ever told them that porn is not real but also that it is harmful. Fight the New Drug is all about education so they remind us that the best thing we parents can do is talk to our kids about porn.  And I know a book that will give you all the help you need for that! I wrote It's Time to Talk to Your Kids About Porn and you can purchase it right here. You don't have to have those conversations alone.  Where to find Fight the New Drug: Find their website here Find their info for parents here Get Fast Facts to share with your teens/young adults here Find out about the live events here Listen to their podcast here Watch their videos on You Tube here Find them on Instagram here  The Greta Eskridge Podcast is a part of the Christian Parenting Podcast Network. For more information visit www.ChristianParenting.org

What if understanding the effects of pornography could empower people to make healthier choices? In this episode, I speak with Parker Hymas from Fight the New Drug, a nonprofit dedicated to raising awareness about the harmful effects of pornography through research, facts, and personal stories. Parker dives into the organization's mission to educate people — especially young audiences — on how porn impacts the brain, mental health, and society. The conversation explores the rise in pornography consumption during COVID-19, its broader societal effects, and the critical role parents play in guiding their children toward healthier habits.Links Discussed in This Episode |Book: Good Pictures, Bad Pictures Jr. by Kristen JensonJo Robertson Episode (Fight the New Drug)TEDx Talk—Tips from a Sex Therapist on Talking to Your Kids About PornConnect with Fight the New Drug:Instagram: https://www.instagram.com/fightthenewdrug/ Website: https://fightthenewdrug.org/parents/Parent Resources: ftnd.org/parentsGeneral Resources: ftnd.org/resourcesFast Facts: ftnd.org/fastfactsDocumentary: ftnd.org/bhwPodcast: ftnd.org/podcastAbout Parker Hymas |Parker Hymas is the Director of Public Outreach at Fight the New Drug, which is a non-religious, non-legislative, educational organization that works with experts, researchers, celebrities, professional athletes, award-winning journalists, CEOs, authors, influencers, and advocates from across all industries to share about the harms of pornography, and how we can address it in our society.Episode Sponsors |The Minimalist Moms Podcast would not be possible without the support of weekly sponsors. Choosing brands that I believe in is important to me. I only want to recommend brands that I believe may help you in your daily life. As always, never feel pressured into buying anything. Remember: if you don't need it, it's not a good deal!Enjoy the Podcast?Post a review and share it! If you enjoyed tuning into this podcast, then do not hesitate to write a review. You can also share this with your fellow mothers so that they can be inspired to think more and do with less. Order (or review) my book, Minimalist Moms: Living & Parenting With Simplicity.Questions |You can contact me through my website, find me on Instagram, Pinterest or like The Minimalist Moms Page on Facebook.Checkout the Minimalist Moms Podcast storefront for recommendations from Diane.If you've been struggling with motivation to declutter or work through bad habits that keep you stuck, I'd love to help you achieve your goals! We'll work together (locally or virtually) to discover what areas in your life are high priority to get you feeling less overwhelmed right away.  For more info on my processes, fees, and availability please contact!Our Sponsors:* Check out Acorns: https://acornsearly.com/MINIMALIST* Check out Armoire and use my code MINIMALIST for a great deal: https://www.armoire.style* Check out Avocado Green Mattress: https://avocadogreenmattress.com* Check out Happy Mammoth and use my code MINIMALIST for a great deal: https://happymammoth.comSupport this podcast at — https://redcircle.com/minimalist-moms-podcast2093/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Reporting for duty & sharing your weekly small talk survival guide! Share these 5 funny, interesting, trending stories and see the magic of small talk unfold - build relationships with patients and bond with coworkers with these stories: 00:00 - 03:02 intro03:02 - end: 1. https://people.com/forever-21-closing-us-stores-after-filing-for-bankruptcy-second-time-116981552. https://nypost.com/2025/03/15/lifestyle/four-seasons-launches-exclusive-vacation-to-sets-where-white-lotus-was-filmed-for-wealthy-fans/3. https://www.nbcnews.com/science/space/boeing-starliner-nasa-astronauts-return-suni-williams-butch-wilmore-rcna1949264. https://www.foodandwine.com/medication-safe-grapefruit-volcani-institute-israel-116941825. https://people.com/will-smith-announces-release-date-for-first-full-length-album-in-20-years-11697678

Some hugely profitable drugs are targeted under new price controls. Big Pharma has been spending millions to fight them tooth and nail.Order Sharyl's new bestselling book: “Follow the $cience.” Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.